A Canadian natural health product company claims to have formulated a hemp extract with superior qualities in comparison to the more widely known cannabis-derived health remedy, CBD.
On Monday, Cannanda released statements and a list of characteristics attributable to its terpene-based CB2 oil product.
The company claims the extract is a safer alternative to CBD that has been offering fast relief for thousands of Canadian citizens.
Read more: PHCO2 launches potent and patented ‘Aquazome’ CBD extract
Read more: CBD legalization worldwide shaping up the market’s future growth: Frost & Sullivan
“The benefit of CB2 oil is that it side-steps every problem that plagues CBD; problems like adverse drug interactions, unanswered questions regarding safety, undisclosed THC, and other quality issues. CB2 oil also has double the success rate compared to CBD, and has a much more direct benefit on pain, arthritis, and other inflammatory conditions,” said Lee Know, co-founder of Cannanda.
Cannanda says that its CB2 extract does not cause adverse drug interactions/reactions like CBD can when a consumer is taking various medications, which is potentially dangerous. The company also claims the product is far less expensive than CBD merchandise.
The extract producer says CB2 is a safer alternative to CBD for athletes and employees who may be subject to drug testing due to the fact that CBD products can often have an undisclosed amount of THC in them due to inadequate quality control measures.
CB2 has 100 per cent GRAS status, according to the company, meaning that it is generally recognized as safe by the FDA. Cannanda says that CBD has had that status revoked.
It also has a 60-70 per cent success rate (roughly 2/3 people find that it works) and the company claims that CBD only has a 33 per cent success rate. Additionally, it has superior bioavailability when compared to the poor absorption of CBD, and the company also claims that it activates “CB2 receptors” in the body whereas CBD does not activate any receptors.
